Plaque-type Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque-type Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis [Phase 2]
Phase II study assessing efficacy and safety of AUR101 in moderate-to-severe chronic plaque-type psoriasis has completed with results posted…
-
CLINICAL_TRIALS withdrawal · 2022-02-24Clinical Trial Update: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012) [Phase 3]
Phase 3 trial evaluating subcutaneous MK-3222 for plaque-type psoriasis has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis [Phase 3]
A Phase 3 pediatric trial in children and adolescents with severe plaque psoriasis has completed; results were posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-02-25Clinical Trial Update: Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab [Phase 2]
Phase 2 trial comparing secukinumab to guselkumab in clearing psoriatic plaques refractory to ustekinumab has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis [Phase 2]
Phase 2 pharmacokinetic and pharmacodynamic study of CD 2027 spray in adults with plaque-type psoriasis completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis [Phase 3]
Phase 3 trial updating Secukinumab dosage optimization in partial responders with moderate to severe plaque psoriasis has completed; results…
-
CLINICAL_TRIALS trial_result · 2019-04-23Clinical Trial Update: A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) [Phase 3]
Phase 3 trial update evaluating secukinumab 300 mg in adults with moderate-to-severe plaque psoriasis; completed with posted results in 2019…
-
CLINICAL_TRIALS trial_result · 2018-12-20Clinical Trial Update: Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab [Phase 3]
Extension study update for secukinumab prefilled syringes in adults with moderate to severe chronic plaque-type psoriasis completing precedi…
-
CLINICAL_TRIALS trial_result · 2018-09-27Clinical Trial Update: Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) [Phase 3]
Phase 3 trial evaluating secukinumab via AutoiNjector for plaque-type psoriasis; study completed with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2017-12-05Clinical Trial Update: AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis [Phase 2]
Phase 2 extension study results for AIN457 regimen in moderate to severe plaque-type psoriasis have been completed with results posted in 20…
-
CLINICAL_TRIALS trial_result · 2014-11-13Clinical Trial Update: Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) [Phase 2]
Phase 2 trial update on apremilast (CC-10004) for moderate-to-severe plaque-type psoriasis with efficacy and safety findings completed.